TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01540825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Low dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: High dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Medium dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Low dose powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Low dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: High dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: High dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Medium dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Medium dose powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Low dose powder for oral solution
Study: NCT03511534

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Evidenced based psychotherapy by a trained psychologist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy
Description: Pharmacotherapy by a psychiatrist
Study: NCT00709111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
Study: NCT02398448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyloprim® 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg; undergranulated, high hardness condition
Description: There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg; alternative condition 2
Description: There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg; alternative condition 3
Study: NCT05109286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CrossFit
Description: CrossFit training
Study: NCT01580865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
Description: Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis
Description: Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
Study: NCT02438891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
Study: NCT04012034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency A
Description: Application of radiofrequency for 30 minutes per week during 8 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency B
Description: Application of radiofrequency without energy for 30 minutes per week during 8 weeks
Study: NCT03203499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS-6637 Oral Tablet
Description: Ascending single doses administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo administered orally.
Study: NCT02267603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03100799

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopy
Description: Arthroscopy of the target knee

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthrocentesis
Description: Arthrocentesis of the target knee and contralateral knee (if patient consents)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: MRI with and without a gadolinium-based contrast agent
Study: NCT03319407

Intervention type: DEVICE
Group type: OTHER
Intervention: EPAD monitoring system
Description: EPAD system will be used as part of routine care
Study: NCT00943709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin glargine recombinant
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine recombinant
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic insulin
Description: Given subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic insulin
Description: Given subcutaneously
Study: NCT03794583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil solution
Description: Inhaled treprostinil solution per dose and schedule specified in the arm
Study: NCT02851420

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: spectroscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spectroscopy
Study: NCT04179747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Psychotherapy
Description: The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate 50Mg Tab
Description: The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
Study: NCT01509079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Cholecalciferol capsule, 4000IU, daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: cholecalciferol capsule, 600 IU, daily for 6 months
Study: NCT04595253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days.
Study: NCT01956734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DNX2401 and Temozolomide
Description: Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection.
Study: NCT05378646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma human recombinant (IFN-G)
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT01165372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate or dihydroartemisinin-piperaquine
Description: artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate or dihydroartemisinin-piperaquine
Description: artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate or dihydroartemisinin-piperaquine
Description: artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
Study: NCT00929604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-1 viral load testing
Description: Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
Study: NCT00698204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Subject was asked to take celecoxib each day that radiation therapy was given.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subject was asked to take placebo each day that radiation therapy was given.
Study: NCT02290860

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Type 2 diabetes diagnosis test
Description: Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
Study: NCT02224599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPA-pulsed DC vaccine
Description: Subjects will given the vaccine which contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Pill
Description: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod Topical Cream
Description: Topical Imiquimod Cream will be applied after vaccination.
Study: NCT00314249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral administration, twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran 100mg
Description: Milnacipran 100mg per day (50mg BID \[twice a day\])
Study: NCT03120806

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted subcuticular skin closure
Description: skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous subcuticular skin closure
Description: skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
Study: NCT00868426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Batch 1
Description: Single, inhaled dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Batch 2
Description: Single, inhaled dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Batch 1 and charcoal
Description: Single, inhaled dose
Study: NCT02067442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acetaminophen
Description: 1000 milligrams given orally before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous acetaminophen
Description: 1000 milligrams of intravenous acetaminophen given before surgery
Study: NCT04532216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device
Description: Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional surgery
Description: Tendon transfer
Study: NCT04679753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)
Description: Brainsway DTMS with iTBS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway DTMS with High Frequency (HF) Stimulation
Description: Brainsway DTMS with HF
Study: NCT02316184

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Advice
Study: NCT01672567

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg supplementation
Description: Daily consumption of 2 eggs for breakfast for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg substitute
Description: Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
Study: NCT01092975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine solution
Description: Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
Study: NCT04440189

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: GID SVF-2 Device System
Description: The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2 Device System
Description: The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.
Study: NCT00144612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/2weeks
Study: NCT04434196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: CC-99282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab
Study: NCT03747978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril and Amlodipine
Description: Fixed combination of Perindopril 5mg and Amlodipine 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril-indapamide
Description: Perindopril 5mg and Indapamide 1.25mg
Study: NCT00057356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study: NCT00780013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride liquid 500 mg per 5 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride liquid 500 mg per 5 mL
Study: NCT01805960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03706495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Group I Postural Exercise
Description: Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Group II Three-dimensional Exercise Therapy Program
Description: The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
Study: NCT04323085

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-in-Noise Treatment Program
Description: Speech therapy program for hypophonia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech-to-Noise Feedback Device Program
Description: Speech Feedback device program for hypophonia.
Study: NCT00344565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy--Relapse Prevention
Description: Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy--Relapse Prevention
Description: Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
Study: NCT05573776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy, High Protein supplement
Description: patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
Study: NCT02882542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.